Version 1
: Received: 10 February 2024 / Approved: 10 February 2024 / Online: 12 February 2024 (09:52:14 CET)
How to cite:
Toniolo, A. Q.; Maccari, G.; Camussi, G. Mucosal mRNA Vaccines. Merits and Perspectives. Preprints2024, 2024020614. https://doi.org/10.20944/preprints202402.0614.v1
Toniolo, A. Q.; Maccari, G.; Camussi, G. Mucosal mRNA Vaccines. Merits and Perspectives. Preprints 2024, 2024020614. https://doi.org/10.20944/preprints202402.0614.v1
Toniolo, A. Q.; Maccari, G.; Camussi, G. Mucosal mRNA Vaccines. Merits and Perspectives. Preprints2024, 2024020614. https://doi.org/10.20944/preprints202402.0614.v1
APA Style
Toniolo, A. Q., Maccari, G., & Camussi, G. (2024). Mucosal mRNA Vaccines. Merits and Perspectives. Preprints. https://doi.org/10.20944/preprints202402.0614.v1
Chicago/Turabian Style
Toniolo, A. Q., Giuseppe Maccari and Giovanni Camussi. 2024 "Mucosal mRNA Vaccines. Merits and Perspectives" Preprints. https://doi.org/10.20944/preprints202402.0614.v1
Abstract
This review highlights the potential and limitations of mRNA vaccines with a particular focus on mucosal delivery as an alternative to parenteral administration. The strengths of mRNA vaccines are: a) Versatility: they can be adapted to target a wide range of pathogens; b) Faster development: designed and produced more quickly than traditional vaccines; c) High efficacy: effective in preventing severe disease, as demonstrated during the COVID-19 pandemic. Current challenges: a) Delivery: current methods (mainly intramuscular injection) may not be optimal for inducing mucosal immunity; b) Stability: mRNA is fragile and needs to be protected from degradation; c) Safety: potential side effects, including myocarditis, blood clotting, allergic reactions need further investigation. Mucosal delivery could be more effective in preventing the transmission of pathogens and is generally better accepted by the population. Pros: offers the potential to induce local immunity at the site of pathogen entry, potentially providing broader protection; Cons: developing effective delivery systems and adjuvants for mucosal delivery is difficult. Extracellular vesicles as a mucosal delivery system are promising and offer a potentially safe, scalable, and needle-free approach. Future directions: a) Optimizing mRNA constructs: strategies like codon optimization and self-amplifying RNA can improve stability and translation efficiency; b) Rigorous pre-clinical studies are essential before human trials.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.